BioRestorative Therapies Inc BRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.36
- Day Range
- $0.36–0.41
- 52-Week Range
- $0.16–2.05
- Bid/Ask
- $0.38 / $0.38
- Shares Outstanding
- 25.48M
- Market Cap
- $10.05M
- Volume/Avg
- 1M / 13M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.biorestorative.com
Valuation
|
Metric
|
BRTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.37 |
Price/Sales | 12.67 |
Price/Cash Flow | — |
Price/Earnings
BRTX
Financial Strength
|
Metric
|
BRTX
|
|---|---|
Quick Ratio | 2.23 |
Current Ratio | 2.35 |
Interest Coverage | — |
Quick Ratio
BRTX
Profitability
|
Metric
|
BRTX
|
|---|---|
Return on Assets (Normalized) | −187.10% |
Return on Equity (Normalized) | −376.00% |
Return on Invested Capital (Normalized) | −374.73% |
Return on Assets
BRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bpzbtjjmz | Qvrlt | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Blpxzvb | Lznsz | $65B | |||
| argenx SE ADR
ARGX
| Pkwyxlq | Zyj | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xhnkvcyz | Vwgdch | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Prljplwhl | Ynpbvy | $25B | |||
| BioNTech SE ADR
BNTX
| Npbbwzfw | Jslx | $22B | |||
| Incyte Corp
INCY
| Ljhsydlq | Mpd | $21B | |||
| Moderna Inc
MRNA
| Mmrtvgmv | Cshvm | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Zwzmgldm | Hxnw | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Hhlzdxzn | Tyjs | $13B |
United States